U.S. Patent and Trademark Office Grants Patent to PositiveID Corporation for Portable Pathogen Detection
This U.S. Patent Covers the Company's Portable Pathogen Detection Devices, Derived From Its M-BAND System, Which is Positioned to Take Advantage of DHS' $3 Billion BioWatch Program
Press Release: PositiveID Corporation – Tue, Dec 6, 2011 8:30 AM EST
DELRAY BEACH, Fla., Dec. 6, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCBB: PSID.OB - News), a developer of medical technologies and molecular diagnostic systems, announced today the U.S. Patent and Trademark Office has granted the Company Patent No. 8,053,214, "Apparatus and Method for Extracting and Analyzing an Analyte from a Fluid-Based Sample." The patent was awarded to PositiveID's MicroFluidic Systems ("MFS") subsidiary, which maintains a strong and growing patent portfolio, the targeted applications of which are biological sample collection processing and detection from environmental samples and clinical samples.
William J. Caragol, Chief Executive Officer of PositiveID, said, "This latest U.S. Patent demonstrates the vast array of derivative technology stemming from M-BAND, a system developed under a decade of funding received from DHS exceeding $35 million. We believe M-BAND continues to be well positioned as a proven technology to compete for DHS' Third Generation BioWatch program, a $3 billion program to identify pathogens in the air as part of an early warning system designed to thwart a potential terrorist attack."
The Company has developed a series of miniaturized, portable microfluidic cartridges for biological sample processing and detection derived from its Microfluidics-based Bioagent Networked Detector (M-BAND), which was developed under funding from the U.S. Department of Homeland Security (DHS). M-BAND is a bioaerosol monitor with fully integrated systems with sample collection, processing and detection modules, used for airborne pathogen detection. The Company's microfluidic cartridges have potential applications ranging from differential extraction cartridges, sample processing and amplification for biodefense applications, to clinical sample processing and detection.
The Company's microfluidic cartridges have been demonstrated to be effective in sample processing and detection of environmental bacteria, such as E. coli; biothreat agents; clinical samples, such as human papilloma virus; antibiotic resistant bacteria, such as MRSA; and forensic applications, such as differential extraction. They have several advantages over other currently available options; they are lower cost, disposable, easy to use, prevent sample to sample contamination, provide fast results, portable, automated, and minimize the likelihood of human error.
MFS' patent portfolio can be categorized into three main technologies, all of which have been demonstrated in real-world applications:
Highly portable systems and devices for biological sample processing and detection, including application to forensic samples, and environmental and diagnostic pathogen samples Fully-automated, stand-alone systems and sub-systems for continuous monitoring for airborne pathogens, including bacteria, viruses and toxins Processes and methods in support of the portable and stand-alone systems, including detection software algorithms.
finance.yahoo.com
|
